| A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India (NCT04153981) | Eli Lilly and Company | 2019-12-16 |
| A Study of LY3526318 in Healthy Women (NCT04183283) | Eli Lilly and Company | 2019-12-12 |
| A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (NCT04188548) | Eli Lilly and Company | 2019-12-10 |
| A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer (NCT04158700) | Eli Lilly and Company | 2019-12-05 |
| A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (NCT04184622) | Eli Lilly and Company | 2019-12-04 |
| A Study of Mirikizumab in Healthy Chinese Participants (NCT04137380) | Eli Lilly and Company | 2019-12-04 |
| A Study of LY900020 in Healthy Chinese Participants (NCT04047940) | Eli Lilly and Company | 2019-11-29 |
| A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation (NCT04165031) | Eli Lilly and Company | 2019-11-28 |
| A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants (NCT04085289) | Eli Lilly and Company | 2019-11-20 |
| A Study of LY3556050 in Healthy Participants (NCT04156750) | Eli Lilly and Company | 2019-11-20 |
| A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (NCT04152382) | Eli Lilly and Company | 2019-11-20 |
| A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) (NCT04166773) | Eli Lilly and Company | 2019-11-19 |
| A Study of LY900014 in Healthy Chinese Participants (NCT04049123) | Eli Lilly and Company | 2019-11-18 |
| A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria (NCT04159701) | Eli Lilly and Company | 2019-11-15 |
| A Study of Lasmiditan in Healthy Chinese Participants (NCT04081324) | Eli Lilly and Company | 2019-11-13 |
| Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (NCT04178967) | Eli Lilly and Company | 2019-10-29 |
| A Study of LY3435151 in Participants With Solid Tumors (NCT04099277) | Eli Lilly and Company | 2019-10-28 |
| A Study of LY3305677 in Participants With Type 2 Diabetes (NCT03928379) | Eli Lilly and Company | 2019-10-27 |
| A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis (NCT04088409) | Eli Lilly and Company | 2019-10-16 |
| Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) (NCT04146363) | Eli Lilly and Company | 2019-09-24 |
| A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer (NCT03988114) | Eli Lilly and Company | 2019-09-16 |
| A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes (NCT04050670) | Eli Lilly and Company | 2019-09-13 |
| A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) (NCT03843125) | Eli Lilly and Company | 2019-09-09 |
| A Study of LY3475766 in Healthy Participants (NCT04052594) | Eli Lilly and Company | 2019-09-03 |
| A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (NCT04039503) | Eli Lilly and Company | 2019-08-30 |
| A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer (NCT04031885) | Eli Lilly and Company | 2019-08-14 |
| A Study of LY3154885 in Healthy Participants (NCT04014361) | Eli Lilly and Company | 2019-08-09 |
| A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body (NCT03955939) | Eli Lilly and Company | 2019-08-02 |
| A Study of LY3214996 in Healthy Participants (NCT04033341) | Eli Lilly and Company | 2019-08-01 |
| A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine (NCT03963232) | Eli Lilly and Company | 2019-07-30 |
| A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (NCT03987919) | Eli Lilly and Company | 2019-07-30 |
| A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (NCT03926130) | Eli Lilly and Company | 2019-07-23 |
| A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine (NCT03988088) | Eli Lilly and Company | 2019-07-22 |
| A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer (NCT03898791) | Eli Lilly and Company | 2019-07-16 |
| A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (NCT03899259) | Eli Lilly and Company | 2019-07-08 |
| Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants (NCT05338502) | Eli Lilly and Company | 2019-07-08 |
| A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis (NCT03942042) | Eli Lilly and Company | 2019-07-05 |
| A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) (NCT03951753) | Eli Lilly and Company | 2019-06-28 |
| A Study of Lasmiditan (LY573144) Over Four Migraine Attacks (NCT03670810) | Eli Lilly and Company | 2019-06-24 |
| A Study of LY3526318 in Healthy Participants (NCT03977974) | Eli Lilly and Company | 2019-06-21 |
| A Drug Interaction Study of LY3154207 in Healthy Participants (NCT03942029) | Eli Lilly and Company | 2019-06-21 |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (NCT03899792) | Eli Lilly and Company | 2019-06-13 |
| A Study of LY3502970 in Healthy Participants (NCT03929744) | Eli Lilly and Company | 2019-06-12 |
| A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone (NCT03954834) | Eli Lilly and Company | 2019-06-03 |
| A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine (NCT03962738) | Eli Lilly and Company | 2019-05-31 |
| A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes (NCT03952130) | Eli Lilly and Company | 2019-05-29 |
| A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes (NCT03952143) | Eli Lilly and Company | 2019-05-27 |
| A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer (NCT03936959) | Eli Lilly and Company | 2019-05-24 |
| A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (NCT03952559) | Eli Lilly and Company | 2019-05-24 |
| A Study of LY3361237 in Participants With Systemic Lupus Erythematosus (NCT03933943) | Eli Lilly and Company | 2019-05-21 |
| A Study of the Effects of LY3372689 on the Brain in Healthy Participants (NCT03944031) | Eli Lilly and Company | 2019-05-08 |
| A Study of Different Injectable Formulations of LY3375880 in Healthy Participants (NCT03913260) | Eli Lilly and Company | 2019-05-01 |
| A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (NCT03915964) | Eli Lilly and Company | 2019-04-25 |
| A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants (NCT05630274) | Eli Lilly and Company | 2019-04-16 |
| A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes (NCT03740919) | Eli Lilly and Company | 2019-04-07 |
| A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (NCT03773965) | Eli Lilly and Company | 2019-04-05 |
| A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes (NCT03882970) | Eli Lilly and Company | 2019-04-01 |
| A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes (NCT03861039) | Eli Lilly and Company | 2019-03-30 |
| A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA (NCT03742973) | Eli Lilly and Company | 2019-03-28 |
| A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes (NCT03890003) | Eli Lilly and Company | 2019-03-28 |
| A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants (NCT03841630) | Eli Lilly and Company | 2019-03-13 |
| A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (NCT03849612) | Eli Lilly and Company | 2019-02-21 |
| A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges (NCT03848767) | Eli Lilly and Company | 2019-02-20 |
| A Study of LY900014 in a Medtronic Pump (NCT03760640) | Eli Lilly and Company | 2019-02-18 |
| A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy (NCT03830281) | Eli Lilly and Company | 2019-02-14 |
| A Study of Selpercatinib (LY3527723) in Healthy Participants (NCT05338515) | Eli Lilly and Company | 2019-02-12 |
| A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis (NCT03831191) | Eli Lilly and Company | 2019-02-12 |
| A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes (NCT03758430) | Eli Lilly and Company | 2019-02-06 |
| A Safety Study of LY3372689 Given By Mouth to Healthy Participants (NCT03819270) | Eli Lilly and Company | 2019-02-05 |
| A Study of LY3405105 in Participants With Advanced Cancer (NCT03770494) | Eli Lilly and Company | 2019-01-31 |
| A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants (NCT05469113) | Eli Lilly and Company | 2019-01-29 |
| Study of Ixekizumab in Healthy Participants (NCT03848403) | Eli Lilly and Company | 2019-01-29 |
| A Study of Ixekizumab in Healthy Participants (NCT03848416) | Eli Lilly and Company | 2019-01-29 |
| An Interaction Study of LY3200882 in Healthy Participants (NCT03792139) | Eli Lilly and Company | 2019-01-08 |
| A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function (NCT05469100) | Eli Lilly and Company | 2018-12-19 |
| A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (NCT03773978) | Eli Lilly and Company | 2018-12-17 |
| A Safety Study of LY3462817 in Healthy Participants (NCT03715192) | Eli Lilly and Company | 2018-12-13 |
| A Study of LY3451838 in Healthy Participants (NCT03692949) | Eli Lilly and Company | 2018-12-11 |
| A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants (NCT05436912) | Eli Lilly and Company | 2018-12-10 |
| A Study of LY3463251 in Healthy Participants (NCT03764774) | Eli Lilly and Company | 2018-12-06 |
| A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis (NCT03750643) | Eli Lilly and Company | 2018-11-29 |
| A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer (NCT03703466) | Eli Lilly and Company | 2018-11-28 |
| A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (NCT03706365) | Eli Lilly and Company | 2018-11-26 |
| A Study of LY3415244 in Participants With Advanced Solid Tumors (NCT03752177) | Eli Lilly and Company | 2018-11-22 |
| A Study of LY3374849 in Healthy Participants (NCT03726125) | Eli Lilly and Company | 2018-11-20 |
| A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk (NCT03730662) | Eli Lilly and Company | 2018-11-20 |
| A Study Comparing User Experience of Different Delivery Devices for Glucagon (NCT03765502) | Eli Lilly and Company | 2018-11-19 |
| A Study of LY3090106 in Japanese and Caucasian Healthy Participants (NCT03736772) | Eli Lilly and Company | 2018-11-19 |
| A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis (NCT03733301) | Eli Lilly and Company | 2018-11-16 |
| A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus (NCT03736785) | Eli Lilly and Company | 2018-11-15 |
| A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D) (NCT03743285) | Eli Lilly and Company | 2018-11-14 |
| A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis (NCT03573323) | Eli Lilly and Company | 2018-11-09 |
| A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD) (NCT03720548) | Eli Lilly and Company | 2018-11-05 |
| A Study of LY3361237 in Healthy Participants (NCT03695198) | Eli Lilly and Company | 2018-10-26 |
| A Study of Mirikizumab in Participants With Plaque Psoriasis (NCT03718884) | Eli Lilly and Company | 2018-10-23 |
| A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT03524092) | Eli Lilly and Company | 2018-10-19 |
| A Study Comparing the Dulaglutide Pen and the Semaglutide Pen (NCT03724981) | Eli Lilly and Company | 2018-10-18 |
| A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (NCT03570749) | Eli Lilly and Company | 2018-09-24 |
| A Study of Two Formulations of LY3074828 in Healthy Participants (NCT03662100) | Eli Lilly and Company | 2018-09-06 |
| A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) (NCT03556202) | Eli Lilly and Company | 2018-09-03 |